--- title: "REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-K: FY2025 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/276939748.md" datetime: "2026-02-25T21:20:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276939748.md) - [en](https://longbridge.com/en/news/276939748.md) - [zh-HK](https://longbridge.com/zh-HK/news/276939748.md) generator: "portal-rs" --- # REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 10-K: FY2025 Revenue: USD 0 Revenue: As of FY2025, the actual value is USD 0. EBIT: As of FY2025, the actual value is USD -1.297 B. Revolution Medicines, Inc. reported a net loss of - $1,131,301 thousand for the year ended December 31, 2025, an increase from - $600,093 thousand in 2024 and - $436,367 thousand in 2023, with an accumulated deficit of - $2.9 billion as of December 31, 2025. The company has never generated revenue from product sales, and collaboration revenue was $0 for 2025 and 2024, down from $11,580 thousand in 2023. #### Operating Expenses - **Research and Development (R&D) Expenses:** Increased by $395.1 million, or 67%, to $987,332 thousand in 2025 from $592,225 thousand in 2024. - **Clinical Development Programs (Third-party R&D):** - Daraxonrasib (RMC-6236): Increased by $162,071 thousand to $330,982 thousand in 2025 from $168,911 thousand in 2024. - Zoldonrasib (RMC-9805): Increased by $56,081 thousand to $120,193 thousand in 2025 from $64,112 thousand in 2024. - Elironrasib (RMC-6291): Increased by $18,637 thousand to $73,671 thousand in 2025 from $55,034 thousand in 2024. - RMC-5127: Incurred $12,824 thousand in 2025, becoming a clinical development program. - RAS companion inhibitors: Decreased by - $6,209 thousand to $746 thousand in 2025 from $6,955 thousand in 2024. - **Preclinical Programs:** Increased by $19,786 thousand to $92,875 thousand in 2025 from $73,089 thousand in 2024. - **Salaries and other employee-related expenses (R&D):** Increased by $75,589 thousand to $189,064 thousand in 2025 from $113,475 thousand in 2024 due to increased headcount. - **Stock-based compensation expense (R&D):** Increased by $27,383 thousand to $78,356 thousand in 2025 from $50,973 thousand in 2024. - **Other research and development costs:** Increased by $29,144 thousand to $87,751 thousand in 2025 from $58,607 thousand in 2024. - **General and Administrative (G&A) Expenses:** Increased by $97.7 million, or 100%, to $195,037 thousand in 2025 from $97,299 thousand in 2024, primarily due to increases in commercial preparation expenses, salaries and other employee-related expenses, stock-based compensation expense, and legal and accounting fees. #### Non-Operating Income (Expense), Net - **Interest income:** Increased by $3.8 million to $90,694 thousand in 2025 from $86,883 thousand in 2024, attributed to a larger cash equivalents and marketable securities balance. - **Interest expense:** Increased by $24.2 million to - $24,231 thousand in 2025 from $0 in 2024, due to interest expense and issuance costs amortization under the Royalty Purchase Agreement. - **Change in fair value of warrant liability and contingent earn-out shares:** Resulted in an expense of - $15,358 thousand in 2025, compared to an income of $4,323 thousand in 2024, primarily due to an increase in the fair value of warrant liability from a share price increase. #### Cash Flow - **Net cash used in operating activities:** Increased to - $897,741 thousand in 2025 from - $557,436 thousand in 2024. - **Cash and cash equivalents:** Totaled $383,745 thousand as of December 31, 2025, down from $543,064 thousand as of December 31, 2024. - **Marketable securities:** Totaled $1,641,934 thousand as of December 31, 2025, down from $1,746,235 thousand as of December 31, 2024. - **Total cash, cash equivalents and marketable securities:** Stood at $2.0 billion as of December 31, 2025, compared to $2.3 billion as of December 31, 2024. #### Outlook / Guidance Revolution Medicines, Inc. expects to initiate a first-in-human clinical trial for a new class of RAS(ON) Inhibitors in the fourth quarter of 2026. The company anticipates a clinical readout for the RASolute 302 study in 2L PDAC in the first half of 2026 and expects to substantially complete enrollment in the RASolve 301 study in NSCLC in 2026. Additionally, the company plans to initiate the RASolve 308 study in 1L metastatic RAS G12D NSCLC in the first half of 2026, and the RASolute 309 study in 1L PDAC in the second half of 2026. ### Related Stocks - [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md) ## Related News & Research - [Oil set for second weekly rise as unsettled US-Iran war crimps supply](https://longbridge.com/en/news/296555193.md) - [IREN Just Passed Its Biggest AI Test as Microsoft and Nvidia Bet Billions](https://longbridge.com/en/news/296533962.md) - [Trump Boosted INTC and DELL: Now He Says ‘Do Magnets’—Are MP and USAR Stocks Next?](https://longbridge.com/en/news/296591886.md) - [Why Iovance Biotherapeutics Stock Hit 52-Week High](https://longbridge.com/en/news/296522969.md) - [Broadcom Stabilizes After Google's $120 Billion Marvell Shock](https://longbridge.com/en/news/296529317.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**